You are here

kidney disease

Travere’s Kidney Disease Drug Narrowly Misses Phase III Endpoint, Stock Tanks

Travere’s Kidney Disease Drug Narrowly Misses Phase III Endpoint, Stock Tanks

BioSpace

Travere Therapeutics

clinical trials

Flag link:

ProKidney drops $25.5M on North Carolina manufacturing site for cell therapy prospect

ProKidney drops $25.5M on North Carolina manufacturing site for cell therapy prospect

Fierce Pharma

drug manufacturing

Flag link:

Novartis to acquire kidney disease biotech Chinook for up to $3.5B

Novartis to acquire kidney disease biotech Chinook for up to $3.5B

BioPharma Dive

Chinook Therapeutics

Flag link:

HI-Bio's expectations elevated after pair of phase 2 readouts bolster autoimmune ambitions

HI-Bio's expectations elevated after pair of phase 2 readouts bolster autoimmune ambitions

Fierce Biotech

Human Immunology Bioscience

Flag link:

Goldfinch Bio falls from the sky after failing to find a path forward for kidney treatments

Goldfinch Bio falls from the sky after failing to find a path forward for kidney treatments

Fierce Biotech

Flag link:

As Roche prepares to take a kidney disease drug into PhIII, Ionis fleshes out the data

As Roche prepares to take a kidney disease drug into PhIII, Ionis fleshes out the data

Endpoints

Ionis Pharmaceuticals

Flag link:

Autoimmune drug biotech HI-Bio unveils $120M to root out cellular drivers of disease

Autoimmune drug biotech HI-Bio unveils $120M to root out cellular drivers of disease

MedCity News

Human Immunology Bioscience

autoimmune disease

Flag link:

Tricida’s shares plunge as phase 3 fail seals fate of FDA-rejected kidney disease drug

Tricida’s shares plunge as phase 3 fail seals fate of FDA-rejected kidney disease drug

Fierce Biotech

Flag link:

FDA’s liver safety request set to delay decision on Travere’s kidney drug

FDA’s liver safety request set to delay decision on Travere’s kidney drug

Fierce Biotech

Travere Therapeutics

Flag link:

Regulus reports positive findings from Phase I kidney disease trial

Regulus reports positive findings from Phase I kidney disease trial

Clinical Trials Arena

clinical trials

Flag link:

Where Will Vertex Pharmaceuticals Be in 1 Year?

Where Will Vertex Pharmaceuticals Be in 1 Year?

Motley Fool

Vertex Pharmaceuticals

cystic fibrosis

Flag link:

Novartis' MS drug Gilenya could inspire new chronic kidney disease treatment

Novartis' MS drug Gilenya could inspire new chronic kidney disease treatment

Fierce Biotech

chronic kidney disease

Flag link:

Travere fails to convince regulators to consider accelerated approval for a rare kidney disease — again

Travere fails to convince regulators to consider accelerated approval for a rare kidney disease — again

Endpoints

Travere Therapeutics

Flag link:

Bayer-Ionis' anti-thrombotic med doesn't increase bleeding in phase 2, setting stage for a new type of anticoagulant

Bayer-Ionis' anti-thrombotic med doesn't increase bleeding in phase 2, setting stage for a new type of anticoagulant

Fierce Biotech

Ionis Pharmaceuticals

clinical trials

Flag link:

Is the HIF-PHI class of next-generation kidney drugs doomed in the U.S.?

Is the HIF-PHI class of next-generation kidney drugs doomed in the U.S.?

MedCity News

Flag link:

Sanofi walks away from kidney disease therapy, leaving $25M in milestones out of reach for Regulus

Sanofi walks away from kidney disease therapy, leaving $25M in milestones out of reach for Regulus

Fierce Biotech

Flag link:

Ionis hands off an antisense drug for kidney disease, giving all rights to Roche

Ionis hands off an antisense drug for kidney disease, giving all rights to Roche

Endpoints

Ionis Pharmaceuticals

clinical trials

immunoglobin A nephropathy

Flag link:

Medtronic to Spin Renal Business into New Company

Medtronic to Spin Renal Business into New Company

Medical Devices and Diagnostics Industry

Flag link:

ACC: Bayer’s Kerendia cuts cardio and kidney complications in high-risk patients

ACC: Bayer’s Kerendia cuts cardio and kidney complications in high-risk patients

Fierce Pharma

Flag link:

Vertex Advances VX-147 Into Pivotal Clinical Development for People With APOL1-Mediated Kidney Disease

Vertex Advances VX-147 Into Pivotal Clinical Development for People With APOL1-Mediated Kidney Disease

Yahoo/Businesswire

Vertex Pharmaceuticals

clinical trials

Flag link:

Pages